Dendreon Corporation (NASDAQ: DNDN) shares traded in the range of $3.38 to $3.87 Friday before settling to close at $3.39, a decrease of 26.14 percent. The stock appears to be facing some resistance at the $3.81, $3.87 and $4.34 levels. The company reported an 8 percent year-over-year decline in revenues for the quarter and stated it does not expect to see year-over-year sales growth for Provenge in the second half. Shares of Dendreon have fallen approximately 36.0 percent in 2013.
More information on Dendreon and access to the free equity report can be found at:
Geron Corporation (NASDAQ: GERN) shares traded in the range of $1.46 to $1.68 Friday before settling to close at $1.49, an increase of 16.41 percent. The stock appears to be facing some resistance at $1.54 with some support at the $1.46 and $1.40 levels. Piper Jaffray analyst Charles Duncan has recently upgraded the company’s rating to “overweight” and has also raised his price target on the stock to $4.00. Shares of Geron have gained approximately 5.6 percent in 2013.
More information on Geron and access to the free equity report can be found at:
Nektar Therapeutics (NASDAQ: NKTR) shares traded in the range of $11.01 to $12.91 Friday before settling to close at $12.41, an increase of 13.44 percent. The stock appears to be facing resistance at the $12.69 and $12.88 levels with some support at $11.77. The company reported revenues were $33.9 million for the second quarter of 2013, an increase of 43 percent year-over-year. Shares of Nektar Therapeutics have gained approximately 67.0 percent in 2013.
More information on Nektar Therapeutics and access to the free equity report can be found at:
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares traded in the range of $20.40 to $23.09 Friday before settling to close at $22.69, an increase of 25.36 percent. The stock appears to have some support at the $20.76, $19.74 and $18.68 levels. The company reported Gattex sales totaled $4.8 million for the second quarter of 2013. For 2013, Gattex/Revestive sales are expected to be in the range of $25 to $30 million. Shares of NPS Pharmaceuticals have gained approximately 150.0 percent in 2013.
More information on NPS Pharmaceuticals and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals
Leave a comment...